DOM-CARVEDILOL TABLET

Država: Kanada

Jezik: angleščina

Source: Health Canada

Aktivna sestavina:

CARVEDILOL

Dostopno od:

DOMINION PHARMACAL

Koda artikla:

C07AG02

INN (mednarodno ime):

CARVEDILOL

Odmerek:

6.25MG

Farmacevtska oblika:

TABLET

Sestava:

CARVEDILOL 6.25MG

Pot uporabe:

ORAL

Enote v paketu:

100

Tip zastaranja:

Prescription

Terapevtsko območje:

BETA-ADRENERGIC BLOCKING AGENTS

Povzetek izdelek:

Active ingredient group (AIG) number: 0122683004; AHFS:

Status dovoljenje:

APPROVED

Datum dovoljenje:

2004-02-18

Lastnosti izdelka

PRODUCT MONOGRAPH
PR
DOM-CARVEDILOL
Carvedilol Tablets, House Standard
3.125, 6.25, 12.5 and 25 mg
CONGESTIVE HEART FAILURE AGENT
DOMINION PHARMACAL
6111 Royalmount Ave., Suite 100
Montréal, Québec
H4P 2T4
DATE OF REVISION:
September 1 2016
SUBMISSION CONTROL NO.: 197191
_ _
_Dom-CARVEDILOL Product Monograph _
_ _
_Page 2 of 38 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
.............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................9
DRUG INTERACTIONS
..................................................................................................15
DOSAGE AND ADMINISTRATION
..............................................................................17
OVERDOSAGE
................................................................................................................19
ACTION AND CLINICAL PHARMACOLOGY
............................................................20
STORAGE AND STABILITY
..........................................................................................23
DOSAGE FORMS, COMPOSITION AND PACKAGING
..............................................23
PART II: SCIENTIFIC INFORMATION
...............................................................................25
PHARMACEUTICAL INFORMATION
..........................................................................25
CLINICAL TRIALS
..........................................................................................................26
DETAILED PHARMACOLOGY
.......................